Subsidiaries of Alkermes plc (NASDAQ:ALKS) have filed a patent infringement litigation in a New Jersey court against Teva Pharmaceutical Industries (NYSE:TEVA) regarding Teva’s U.S. application seeking FDA approval of a generic version of alcohol/opioid dependence med Vivitrol (naltrexone for extended-release injectable suspension).
The filing of a lawsuit is routine for branded drugmakers since it automatically triggers a 30-month stay on an FDA nod for a generic to allow time for the patent dispute to be adjudicated.
Vivitrol accounted for almost 29% of Alkermes’ Q2 revenue ($71.6M/247.5M).
https://seekingalpha.com/news/3612824-alkermes-sues-teva-to-block-generic-version-of-vivitrol
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.